Innaxon

Dexamethasone Lipodisq™ Sterile Solution

CHF 244.00

In stock

IAX-700-107-L0011 mlCHF 244.00

More Information
Product Details
Synonyms	MK-125; NSC 34521; 9α-Fluoro-16α-methylprednisolone; 9-Fluoro-11β,17,21-trihydroxy-16α-methyl-pregna-1,4-diene-3,20-dione
Product Type	Chemical
Properties
Formula	C₂₂H₂₉FO₅
MW	392.5
CAS	50-02-2
RTECS	TU3980000
Purity Chemicals	≥95% (HPLC)
Solubility	Soluble in water, PBS, Tris and other physiological solutions as formulated in a proprietary, thermostable, aqueous lipid nanoparticulate formulation (Lipodisq).
Reconstitution	Avoid the use of buffers with divalent ions such as Ca or Mg or pH <6.5 or >8.0, which can cause particle instability. Unformulated dexamethasone is soluble in DMSO, ethanol or methanol.
Formulation	Liquid, detergent-free discoidal nano-formulation made of styrene-maleic acid lipid particles (SMALP), lecithin and sterile water.
Concentration	1mg/ml (0.1% w/vol)
Biological Activity	Discoidal nano-particles can incorporate hydrophobic, poorly water-soluble compounds, such as lipids, lipoproteins and glycolipids. - Cell culture tested (human macrophage cell line) (MTT). - Recommended starting dilution: 1:200 or higher. - Optimal working concentrations depend on the applications and need to be determined. - Published procedures using Lipodisq formulations (Curcumin and IAXO TLR4 antagonists) in vivo rodent models at 3-10mg/kg. Recommended route of administration is subcutaneous (s.c.) with oral or nasal application as a possible alternative, which needs to be optimized.
Declaration	Manufactured by Innaxon.
Other Product Data	Click here for Original Manufacturer Product Datasheet: Our product description may differ slightly from the original manufacturers' product datasheet. Lipodisq™ technology is covered by one or more of the following patents owned by Malvern Cosmeceutics Limited: AU2006253886, CA2611144, CN101184473B, EP1890675, GB2426703, IN261468, JP5142898, US8623414 and WO/2021/005340A1 pending. The purchaser is licensed under those patents to use these assemblies for the purpose of research and development only, but not for the purpose of delivery of agents for clinical use to humans or veterinary use to animals for therapeutic, diagnostic or prophylactic purposes, which uses are specifically prohibited.
InChi Key	UREBDLICKHMUKA-CXSFZGCWSA-N
Smiles	O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@]2(F)[C@@H](O)C[C@@]4(C)[C@@]3([H])C[C@@H](C)[C@]4(O)C(CO)=O)=C1
Shipping and Handling
Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	+4°C
Handling Advice	Keep sterile. Avoid skin and eye contact.
Use/Stability	Stable for at least 1 year after receipt when stored at +4°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product-specific References

Description

Dexamethasone Lipodisq Sterile Solution is a ready-to-use nano-formulated aqueous solution.
Dexamethasone, developed in 1957 and granted FDA approval in 1958, is a corticosteroid structurally similar to hydrocortisone and prednisolone. Dexamethasone is used to treat conditions including: endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, and edematous and most recently COVID-19.
Dexamethasone Lipodisq is based on a nanoparticle (11-40nm) drug delivery system comprising a discoidal phospholipid bilayer membrane stabilized by a chaperone molecule annulus. Internal properties of the phospholipid membrane support the disposition and stabilization of drug molecule candidates and preserve the native conformation of membrane molecules. The resulting encapsulated actives are rendered water-soluble and specialized for intra-cellular penetration/delivery via endosomal uptake mechanisms. Lipodisq solutions show a good safety profile and are suitable for in vitro and in vivo investigations.

Product References

Metabolic imbalance of T cells in COVID-19 is hallmarked by basigin and mitigated by dexamethasone: J.P. Siska, et al.; J. Clin. Invest. 131, e148225 (2021)
Dexamethasone for Severe COVID-19: How Does It Work at Cellular and Molecular Levels? T. Kino, et al.; Int. J. Mol. Sci. 22, 6764 (2021)
Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics: S. Kumar, et al.; Front. Immunol. 12, 752227 (2021)
Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19: S. Sinha, et al.; Nat. Med. 28, 201 (2022)

General References for Lipodisq™ Technology:

Responsive Hydrophobically Associating Polymers: A Review of Structure and Properties: S.R. Tonge & B.J. Tighe; Adv. Drug Deliv. Rev. 53, 109 (2001)
Detergent-free formation and physico-chemical characterization of nanosized lipidpolymer complexes: Lipodisq; M.C. Orwick, et al.; Angew. Chem. 51, 4653 (2012)
Physicochemical Characterization, Toxicity and In Vivo Biodistribution Studies of a Discoidal, Lipid-Based Drug Delivery Vehicle: Lipodisq Nanoparticles Containing Doxorubicin: M.L. Torgersen, et al.; J. Biomed. Nanotechnol. 16, 41 (2020)
Applications of Synthetic Polymer Discoidal Lipid Nanoparticles to Biomedical Research: M. Tanaka; Chem. Pharm. Bull. 70, 507 (2022)
Mechanisms of Formation, Structure, and Dynamics of Lipoprotein Discs Stabilized by Amphiphilic Copolymers: A Comprehensive Review: P.S. Orekhov, et al.; Nanomaterials 12, 361 (2022)

Call	+41 61 926 6040
Fax	+41 61 926 6049